均瑶健康(605388) - 2025 Q2 - 季度业绩预告

Performance Forecast Overview Core Performance Indicators (H1 2025) The company forecasts a significant decline in its H1 2025 performance, with net profit attributable to shareholders expected to decrease by 74.23% to 82.82% and non-recurring net profit by 93.19% to 95.46% H1 2025 Performance Forecast Key Data | Indicator | Estimated Amount (million CNY) | Year-over-Year Change | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | 5.97 - 8.96 | ↓ 74.23% - 82.82% | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) | 1.36 - 2.03 | ↓ 93.19% - 95.46% | - The performance forecast data is unaudited by a certified public accountant[7] Prior Period Performance Review (H1 2024) In H1 2024, the company reported a net profit attributable to shareholders of 34.76 million CNY and a non-recurring net profit of 29.89 million CNY H1 2024 Key Financial Data | Indicator | Amount (million CNY) | | :--- | :--- | | Total Profit | 46.70 | | Net Profit Attributable to Shareholders | 34.76 | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) | 29.89 | - Basic earnings per share for the prior period was 0.06 CNY[8] Analysis of Performance Changes The company attributes the significant decline in current period performance to three main factors: decreased revenue from traditional core ambient lactic acid bacteria beverages, substantial increases in sales and marketing expenses for new product promotion, and increased R&D investment to support long-term development Decline in Traditional Business The company's traditional ambient lactic acid bacteria beverage business experienced reduced revenue compared to the prior year, primarily due to sustained pressure on the consumption environment, leading to decreased market share for dairy-containing beverages and weak downstream customer demand - Due to a challenging consumption environment and weak downstream customer demand, the company's traditional ambient lactic acid bacteria beverage business experienced a year-over-year decline in both revenue and profit[9] Increase in Sales and Marketing Expenses During the reporting period, the company's sales and marketing expenses significantly increased year-over-year, primarily due to upfront investments in e-commerce and new retail channel expansion for new product development, despite rapid growth in new business segments - To develop new product lines, the company expanded into e-commerce and new retail channels, leading to a substantial increase in upfront sales and marketing expenses that compressed current period profits[9] Increased R&D Investment The company increased R&D investment during the reporting period to support future business development, including expanding its subsidiary Junyao Runying's functional strain resource library from over 6,000 to over 40,000 strains and successfully developing low-temperature probiotic beverages - The company increased R&D investment, expanding its subsidiary Junyao Runying's functional strain resource library from over 6,000 strains at the end of last year to over 40,000 strains[9] - The company successfully developed low-temperature probiotic beverages, achieving a business breakthrough, and will continue to invest in R&D to build a probiotic product matrix[9] Risk Warning and Other Matters Risk Warning and Other Explanations The company explicitly states that this performance forecast is a preliminary unaudited result, subject to uncertainty, and advises investors to note investment risks as final accurate financial data will be based on the officially disclosed H1 2025 report - The company emphasizes that this performance forecast is unaudited by a certified public accountant and contains no significant uncertainties affecting its accuracy[11] - Final accurate financial data will be based on the company's officially disclosed H1 2025 report, advising investors to be aware of investment risks[12]